Show simple item record

dc.creatorJoudi, Maryam
dc.creatorMoradi Binabaj, Maryam
dc.creatorPorouhan, Pejman
dc.creatorPeyroShabany, Babak
dc.creatorTabasi, Mohsen
dc.creatorFAZILATPANAH, DANIAL
dc.creatorKhajeh, Mahtab
dc.creatorMehrabian, Arezoo
dc.creatorDehghani, Mansoureh
dc.creatorWelsh, James S.
dc.creatorKeykhosravi, Batol
dc.creatorAkbari Yazdi, Azam
dc.creatorAriamanesh, Mona
dc.creatorGhasemi, Ahmad
dc.creatorFerns, Gordon
dc.creatorAlireza Javadinia, Seyed
dc.date.accessioned2022-04-22T20:27:44Z
dc.date.available2022-04-22T20:27:44Z
dc.date.issued2022-03-01
dc.identifier.citationJoudi M, Moradi Binabaj M, Porouhan P, PeyroShabany B, Tabasi M, Fazilat-Panah D, Khajeh M, Mehrabian A, Dehghani M, Welsh JS, Keykhosravi B, Akbari Yazdi A, Ariamanesh M, Ghasemi A, Ferns G and Javadinia SA (2022) A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome? Front. Endocrinol. 13:798975. doi: 10.3389/fendo.2022.798975
dc.identifier.issn1664-2392
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/7533
dc.identifier.urihttp://hdl.handle.net/20.500.12613/7555
dc.description.abstractAim: To determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer. Methods: In this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 ± 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects. Results: The presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively. Discussion: The inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.
dc.format.extent7 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofCOVID-19 Research
dc.relation.haspartFrontiers in Endocrinology, Vol. 13
dc.relation.isreferencedbyFrontiers Media
dc.rightsAttribution CC BY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBreast cancer
dc.subjectInactivated SARS-CoV-2 vaccine
dc.subjectSeroconversion
dc.subjectSARS-CoV2
dc.subjectCOVID-19 vaccine
dc.subjectCancer
dc.subjectMalignancy
dc.subjectIran
dc.titleA Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
dc.typeText
dc.type.genreJournal article
dc.contributor.groupCenter for Inflammation and Lung Research (Temple University)
dc.relation.doihttps://doi.org/10.3389/fendo.2022.798975
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeLewis Katz School of Medicine
dc.creator.orcidFazilat-Panah|0000-0003-4194-6575
dc.temple.creatorFazilat-Panah, Danial
refterms.dateFOA2022-04-22T20:27:44Z


Files in this item

Thumbnail
Name:
FazilatPanah-JournalArticle-20 ...
Size:
303.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY